Dr. George on Concerns With Immune-Related Adverse Events in RCC

Daniel J. George, MD
Published: Wednesday, Jan 09, 2019



Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses concerns with immune-related adverse events (irAEs) in renal cell carcinoma (RCC).

Anytime immunotherapy is used, there is a risk for side effects that are potentially long lasting, as immunotherapy tends to stay in the body a long time, explains George. When toxicities do present as a result of treatment, they can be slow to resolve. Potential toxicities include rashes, pneumonitis, and colitis. Although rare, they may require a prolonged use of steroids, he explains.

More often than not, treatment is halted until irAEs resolve to grade 1 or less; as such, these events may cause a significant delay in subsequent treatment, says George. However, that does not necessarily equate to a greater likelihood of disease progression. The potential for irAEs has not been a deterrent for the majority of patients, says George, although it does require proactive management to prevent high-grade complications from happening.
SELECTED
LANGUAGE


Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses concerns with immune-related adverse events (irAEs) in renal cell carcinoma (RCC).

Anytime immunotherapy is used, there is a risk for side effects that are potentially long lasting, as immunotherapy tends to stay in the body a long time, explains George. When toxicities do present as a result of treatment, they can be slow to resolve. Potential toxicities include rashes, pneumonitis, and colitis. Although rare, they may require a prolonged use of steroids, he explains.

More often than not, treatment is halted until irAEs resolve to grade 1 or less; as such, these events may cause a significant delay in subsequent treatment, says George. However, that does not necessarily equate to a greater likelihood of disease progression. The potential for irAEs has not been a deterrent for the majority of patients, says George, although it does require proactive management to prevent high-grade complications from happening.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x